Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection

A population pharmacokinetic analysis was performed to investigate the pharmacokinetics of moxifloxacin (400 mg) following a once-daily oral administration in 28 patients with respiratory tract infection disease. The maximum plasma concentration and the area under the plasma concentration–time curve were 3.97 µg/ml and 51.74 µg·h/ml, respectively; these values were nearly equivalent to those of healthy adult men. Two adverse drug reactions (nausea, vomiting) occurred, but both reactions were mild and nonserious and the patients recovered without treatment. The pharmacokinetic profile of moxifloxacin in Japanese patients with respiratory tract infection and an underlying disease should thus be considered safe and comparable with that in healthy adult men, and adjustment of dose may do not need for age, sex, body weight, or renal function.

Source: Therapeutic Advances in Respiratory Disease - February 1, 2016 Category: Respiratory Medicine Authors: Ito, F., Ohno, Y., Toyoshi, S., Kaito, D., Koumei, Y., Endo, J., Kamamiya, F., Mori, H., Mori, M., Morishita, M., Funaguchi, N., Minatoguchi, S. Tags: Original Research Source Type: research